ABBVIE INC. (NYSE:ABBV) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition
financial results for the first quarter ended March 31, 2017. A
copy of the press release is furnished as Exhibit 99.1 to this
report and incorporated herein by reference.
|
Exhibit No.
|
Exhibit
|
|
|
99.1
|
Press Release dated April 27, 2017 (furnished to Item
2.02). |
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
ABBVIE INC.
|
|||
|
Date:
|
April 27, 2017
|
By:
|
/s/ William J. Chase
|
|
William J. Chase
|
|||
|
Executive Vice President,
|
|||
|
Chief Financial Officer
|
|
Exhibit No.
|
Exhibit
|
|
|
99.1
|
Press Release dated April 27, 2017 (furnished
|
About ABBVIE INC. (NYSE:ABBV)
AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company operates in pharmaceutical products segment. Its products are focused on treating conditions, such as chronic autoimmune diseases, in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, as well as other serious health conditions. AbbVie also has a pipeline of new medicines, including over 50 compounds or indications, such as immunology, virology/liver disease, oncology, neurological diseases and women’s health. Its product portfolio includes HUMIRA, IMBRUVICA, HCV products, additional virology products, metabolics/hormones products, endocrinology products and other products. ABBVIE INC. (NYSE:ABBV) Recent Trading Information
ABBVIE INC. (NYSE:ABBV) closed its last trading session down -0.06 at 65.04 with 5,008,927 shares trading hands.
